ABOUT
Liferaft Biosciences
Liferaft Biosciences is a clinical stage biotechnology company with a versatile model that enables us to address high-value, high-impact solutions to unmet therapeutic challenges.
Partnering for Promise & Innovation
Our gaze is fixed on the future, focusing on involving head and neck cancer patients in clinical trials featuring Vepoloxamer. This specialized approach empowers us to gauge Vepoloxamer’s efficacy in addressing the unique challenges presented by severe oral mucositis in this patient cohort.
Through patient participation in meticulously designed clinical trials, we aim to amass invaluable data on Vepoloxamer’s potential to alleviate inflammation, shield mucosal surfaces, and elevate overall patient well-being. This research signifies a pivotal stride toward deepening our comprehension of how Vepoloxamer can profoundly enhance the lives of individuals undergoing radiation therapy for head and neck cancer, offering them a brighter and less painful path toward recovery.
In addition to our efforts in head and neck cancer, we are also dedicated to treating patients with lung cancer who undergo radiation therapy. The esophagus is particularly vulnerable to radiation-induced damage in these cases. Through ongoing research and trials, we aspire to extend the benefits of Vepoloxamer to lung cancer patients, lessening the impact of radiation on the esophagus and improving their quality of life during treatment.
Vepoloxamer’s promise extends even further, with the potential for fewer treatments at higher radiation therapy doses (GY). This is another advancement in the field of radiation cancer treatment.
Patent Portfolio
Vepoloxamer was selected for its high content data supporting safety, pharmacological activity and manufacturability. We have active INDs, and our compound is supported by extensive drug master files.
Our intellectual property is broad and focused on providing exclusivity in key global markets. Our programs are well protected by recently issued and pending patents and well-developed trade secret know-how (complex macromolecule: proprietary manufacturing / characterization).
Patent – Composition of matter
US 9,403,941 (earliest expiration: Aug, 2036)
Corresponding applications pending worldwide
Patent – Use – Methods of Protecting Cells from Insults
Provisional Filed 07/2020 | Issue 07/2022
